MUC16 and ovarian carcinoma: Two multi-marker panels (CA125, HE4, glycodelin, plasminogen, PLAUR, CA15-3, PAI-1 and CA125, CA19-9, EGFR, CRP, myoglobin, ApoA-1, ApoC-III, MIP-1α, IL-6, IL-18, tenascin C) exhibited high sensitivities from 80.5% to 91.3% and specificities from 96.5% to 88.5%, respectively, for the detection of early-stage ovarian cancer [115,116].